Ocumetics Technology Corp. has completed the third and final tranche of its private placement, raising an additional $162,000 and totaling $3.11 million in gross proceeds. The funds will support ongoing first-in-human clinical trials, including surgeries planned in Mexico City, and preparations for an FDA Investigational Device Exemption (IDE) application targeted for early 2027. This financing milestone strengthens Ocumetics' position to advance its innovative intraocular lens technology closer to U.S. clinical pathways and potential market entry. The company issued units consisting of common shares and warrants, with proceeds primarily allocated to research, development, and working capital.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
